Modelling the Lymphatic Metastatic Progression Pathways of OPSCC from Multi-Institutional Datasets
Authors:
Roman Ludwig,
Adrian Schubert,
Dorothea Barbatei,
Lauence Bauwens,
Jean-Marc Hoffmann,
Sandrine Werlen,
Olgun Elicin,
Matthias Dettmer,
Philippe Zrounba,
Bertrand Pouymayou,
Panagiotis Balermpas,
Vincent Grégoire,
Roland Giger,
Jan Unkelbach
Abstract:
The elective clinical target volume (CTV-N) in oropharyngeal squamous cell carcinoma (OPSCC) is currently based mostly on the prevalence of lymph node metastases in different lymph node levels (LNLs) for a given primary tumor location. We present a probabilistic model for ipsilateral lymphatic spread that can quantify the microscopic nodal involvement risk based on an individual patient's T-catego…
▽ More
The elective clinical target volume (CTV-N) in oropharyngeal squamous cell carcinoma (OPSCC) is currently based mostly on the prevalence of lymph node metastases in different lymph node levels (LNLs) for a given primary tumor location. We present a probabilistic model for ipsilateral lymphatic spread that can quantify the microscopic nodal involvement risk based on an individual patient's T-category and clinical involvement of LNLs at diagnosis. We extend a previously published hidden Markov model (HMM), which models the LNLs (I, II, III, IV, V, and VII) as hidden binary random variables (RVs). Each represents a patient's true state of lymphatic involvement. Clinical involvement at diagnosis represents the observed binary RVs linked to the true state via sensitivity and specificity. The primary tumor and the hidden RVs are connected in a graph. Each edge represents the conditional probability of metastatic spread per abstract time-step, given disease at the edge's starting node. To learn these probabilities, we draw Markov chain Monte Carlo samples from the likelihood of a dataset (686 OPSCC patients) from three institutions. We compute the model evidence using thermodynamic integration for different graphs to determine which describes the data best. The graph maximizing the model evidence connects the tumor to each LNL and the LNLs I through V in order. It predicts the risk of occult disease in level IV is below 5% if level III is clinically negative, and that the risk of occult disease in level V is below 5% except for advanced T-category (T3 and T4) patients with clinical involvement of levels II, III, and IV. The provided statistical model of nodal involvement in OPSCC patients trained on multi-institutional data may guide the design of clinical trials on volume-deescalated treatment of OPSCC and contribute to more personal guidelines on elective nodal treatment.
△ Less
Submitted 21 December, 2023; v1 submitted 18 December, 2023;
originally announced December 2023.
Federated Learning Enables Big Data for Rare Cancer Boundary Detection
Authors:
Sarthak Pati,
Ujjwal Baid,
Brandon Edwards,
Micah Sheller,
Shih-Han Wang,
G Anthony Reina,
Patrick Foley,
Alexey Gruzdev,
Deepthi Karkada,
Christos Davatzikos,
Chiharu Sako,
Satyam Ghodasara,
Michel Bilello,
Suyash Mohan,
Philipp Vollmuth,
Gianluca Brugnara,
Chandrakanth J Preetha,
Felix Sahm,
Klaus Maier-Hein,
Maximilian Zenk,
Martin Bendszus,
Wolfgang Wick,
Evan Calabrese,
Jeffrey Rudie,
Javier Villanueva-Meyer
, et al. (254 additional authors not shown)
Abstract:
Although machine learning (ML) has shown promise in numerous domains, there are concerns about generalizability to out-of-sample data. This is currently addressed by centrally sharing ample, and importantly diverse, data from multiple sites. However, such centralization is challenging to scale (or even not feasible) due to various limitations. Federated ML (FL) provides an alternative to train acc…
▽ More
Although machine learning (ML) has shown promise in numerous domains, there are concerns about generalizability to out-of-sample data. This is currently addressed by centrally sharing ample, and importantly diverse, data from multiple sites. However, such centralization is challenging to scale (or even not feasible) due to various limitations. Federated ML (FL) provides an alternative to train accurate and generalizable ML models, by only sharing numerical model updates. Here we present findings from the largest FL study to-date, involving data from 71 healthcare institutions across 6 continents, to generate an automatic tumor boundary detector for the rare disease of glioblastoma, utilizing the largest dataset of such patients ever used in the literature (25,256 MRI scans from 6,314 patients). We demonstrate a 33% improvement over a publicly trained model to delineate the surgically targetable tumor, and 23% improvement over the tumor's entire extent. We anticipate our study to: 1) enable more studies in healthcare informed by large and diverse data, ensuring meaningful results for rare diseases and underrepresented populations, 2) facilitate further quantitative analyses for glioblastoma via performance optimization of our consensus model for eventual public release, and 3) demonstrate the effectiveness of FL at such scale and task complexity as a paradigm shift for multi-site collaborations, alleviating the need for data sharing.
△ Less
Submitted 25 April, 2022; v1 submitted 22 April, 2022;
originally announced April 2022.
